- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05549206
A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People
March 15, 2023 updated by: AIM Vaccine Co., Ltd.
A Cohort Study to Evaluate Safety and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China
This is a cohort study to evaluate safety and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
350
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Huan Zhou
- Phone Number: 05523086943
- Email: byyfygcp@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age at the time of first dose of vaccine: adults aged 18-59 years (including boundary values), elderly ≥60 years, both sexes;
- Armpit temperature <37.3℃ on the day of enrollment;
- Based on the medical history and relevant physical examination and laboratory examination results, the investigator clinically determined that the patient was in good health;
- Subjects have independent judgment ability, can read, understand and complete vaccination diary cards, and they participate voluntarily and sign an informed consent form.
Exclusion Criteria:
- The subject has a history of SARS-CoV-2 or SARS infection, or has a history of contact with SARS-CoV-2 infected persons (nucleic acid test positive) or suspected infected persons within 30 days before screening, or living abroad within 30 days before screening history, or a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 IgM or IgG test before the first dose of vaccine;
- History of allergy to any component of the study vaccine or a history of a severe allergic reaction to the vaccine or drug (including but not limited to anaphylactic shock, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, or local anaphylactic necrosis [Arthus reaction]);
- Upon questioning, have a history of COVID-19 vaccination, or have received other inactivated vaccines within 14 days before screening, and received live attenuated vaccines within 28 days;
- Patients have a medical history or family history of epilepsy, convulsions, neurological diseases and mental diseases;
- There are contraindications for intramuscular injection, such as: thrombocytopenia that has been diagnosed, any coagulation disorder or receiving anticoagulant treatment, etc.;
- The investigator judges that he is known or suspected of having more serious diseases at the same time, including but not limited to: respiratory diseases (tuberculosis, lung failure, etc.), liver and kidney diseases, cardiovascular diseases (heart failure, severe hypertension, etc.), Malignant tumor, infection or allergic skin disease, HIV infection (test report can be provided), or during the active period of acute infection or chronic disease (within 3 days before vaccination);
- Congenital malformations, developmental disorders, or chronic diseases that the investigator judges are not suitable for participating in this study (such as Downs syndrome, sickle cell anemia or neurological disorders, Guillain-Barre syndrome, etc.), excluding stable diabetes/hypertension );
- Patients with known immunological impairment or low immunological function diagnosed by the hospital before enrollment, or functional asplenia or splenectomy caused by any situation;
- During the screening period, laboratory tests (ALT, AST, troponin, D-dimer) and electrocardiogram abnormalities were clinically significant;
- Those with evidence of tobacco, alcohol, and drug abuse, and those who did not agree to abstain from smoking and drinking during the study period;
- Female: those who have a positive blood pregnancy test, are pregnant, breastfeeding, or have a pregnancy plan within one year; men: whose spouse has a pregnancy plan within one year;
- Patients have participated in other clinical trials (drugs, biological products or devices) within 3 months before the first dose of vaccine, or plan to participate in other clinical trials during the research period;
- Patients received immune enhancement or immunosuppressive therapy within 6 months before the first dose of vaccine (continuous oral or instillation for more than 14 days);
- Patients donated blood ≥400 ml within 28 days before screening, or received whole blood, plasma and immunoglobulin therapy within 6 months before screening;
- Currently receiving research drug treatment to prevent COVID-19;
- Patients are taking antipyretic, analgesic and anti-allergic drugs within 3 days before enrollment;
- The investigator judges that the subjects cannot follow the research procedures, comply with the agreement, or plan to permanently relocate from the area before the end of the research, or plan to leave the local area for a long time during the scheduled visit period;
- The relevant staff involved in this study or their immediate family members (such as spouses, parents, siblings or children);
- According to the investigator's judgment, there are other situations that are not suitable for participating in this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 50μg
Two doses were administered by intramuscular injection, 28 days apart
|
50μg/dose
|
Experimental: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine 100μg
Two doses were administered by intramuscular injection, 28 days apart
|
100μg/dose
|
Placebo Comparator: Placebo
Two doses were administered by intramuscular injection, 28 days apart
|
Saline solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
SARS-CoV-2 Novel coronavirus S protein antibody (IgG) level
Time Frame: At 28 days after full immunization
|
At 28 days after full immunization
|
The levels of neutralizing antibodies of SARS-CoV-2 anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus
Time Frame: At 28 days after full immunization
|
At 28 days after full immunization
|
The levels of neutralizing antibodies of SARS-CoV-2 anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus
Time Frame: At 28 days after full immunization
|
At 28 days after full immunization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Within 14 days and 28 days after each dose of immunization
|
Within 14 days and 28 days after each dose of immunization
|
|
Incidence of adverse events associated with the study vaccine
Time Frame: Within 14 days and 28 days after each dose of immunization
|
Within 14 days and 28 days after each dose of immunization
|
|
Incidence of SAE
Time Frame: Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
|
Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
|
|
Incidence of AESI
Time Frame: Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
|
Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
|
|
Incidence of SAE associated with the study vaccine
Time Frame: Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
|
Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
|
|
Incidence of AESI associated with the study vaccine
Time Frame: Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
|
Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization
|
|
Incidence of grade ≥3 adverse events
Time Frame: Within 28 days after each dose/full dose
|
Adverse events were graded from pain, tenderness, itching, induration, swelling and other aspects, and the higher the grade, the more serious the adverse events were
|
Within 28 days after each dose/full dose
|
Incidence of grade ≥3 adverse events associated with the study vaccine
Time Frame: Within 28 days after each dose/full dose
|
Adverse events were graded from pain, tenderness, itching, induration, swelling and other aspects, and the higher the grade, the more serious the adverse events were
|
Within 28 days after each dose/full dose
|
Statistics of withdrawal from the study due to adverse events
Time Frame: Within 28 days after each dose/full dose
|
Within 28 days after each dose/full dose
|
|
The level of SARS-CoV-2 S protein antibody (IgG)
Time Frame: At 14 days, 3 months, 6 months, and 12 months after full immunization
|
At 14 days, 3 months, 6 months, and 12 months after full immunization
|
|
The positive conversion rate of SARS-CoV-2 S protein antibody
Time Frame: At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
|
At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
|
|
True virus neutralizing antibody levels of SARS-CoV-2 (Omicron strain BA.2, BA.4, BA.5, Delta strain)
Time Frame: At 14 days, 3 months, 6 months, and 12 months after full immunization
|
At 14 days, 3 months, 6 months, and 12 months after full immunization
|
|
Pseudovirus neutralizing antibody levels of SARS-CoV-2 (Omicron strain BA.2, BA.4, BA.5, Delta strain)
Time Frame: At 14 days, 3 months, 6 months, and 12 months after full immunization
|
At 14 days, 3 months, 6 months, and 12 months after full immunization
|
|
Positive conversion rates of neutralizing antibodies against true virus of SARS-CoV-2 (Omicron strain BA.2, BA.4, BA.5, Delta strain)
Time Frame: At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
|
At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
|
|
Positive conversion rates of neutralizing antibodies against pseudovirus of SARS-CoV-2 (Omicron strain BA.2, BA.4, BA.5, Delta strain)
Time Frame: At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
|
At 14 days, 28 days, 3 months, 6 months, and 12 months after full immunization
|
|
Cellular immune response levels (IFN-γ) against Novel coronavirus (2019-nCoV)(ELISPOT)
Time Frame: At 7 days , 14 days , and 28 days after complete immunization
|
At 7 days , 14 days , and 28 days after complete immunization
|
|
Cellular immune response levels ( IL-2) against Novel coronavirus (2019-nCoV)(ELISPOT)
Time Frame: At 7 days , 14 days , and 28 days after complete immunization
|
At 7 days , 14 days , and 28 days after complete immunization
|
|
Cellular immune response levels (IL-4) against Novel coronavirus (2019-nCoV)(ELISPOT)
Time Frame: At 7 days , 14 days , and 28 days after complete immunization
|
At 7 days , 14 days , and 28 days after complete immunization
|
|
Cellular immune response levels (IL-13) against Novel coronavirus (2019-nCoV)(ELISPOT)
Time Frame: At 7 days , 14 days , and 28 days after complete immunization
|
At 7 days , 14 days , and 28 days after complete immunization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2023
Primary Completion (Anticipated)
April 1, 2023
Study Completion (Anticipated)
April 1, 2024
Study Registration Dates
First Submitted
September 18, 2022
First Submitted That Met QC Criteria
September 20, 2022
First Posted (Actual)
September 22, 2022
Study Record Updates
Last Update Posted (Actual)
March 16, 2023
Last Update Submitted That Met QC Criteria
March 15, 2023
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LVRNA012-IIT-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
Arcturus Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeActive, not recruiting
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and PreventionCompleted
Clinical Trials on SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
AIM Vaccine Co., Ltd.Ningbo Rongan Biological Pharmaceutical Co. Ltd.; LiveRNA Therapeutics Inc.Not yet recruiting
-
BioNTech SEPfizerRecruitingCOVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 | SARS-CoV-2 VirusUnited States, Brazil, Puerto Rico
-
NovavaxActive, not recruitingCOVID-19 | SARS CoV 2 InfectionAustralia
-
NovavaxActive, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
NovavaxNot yet recruiting
-
University of MelbourneSouthern Star Research Pty Ltd.Completed